Trials / NCT01736059
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
Underway, not enrolling Phase 1 Cell therapy
- Sponsor
- University of California, Davis
- Treatment
- CD34+ bone marrow stem cells intravitreal
- Gene
- Not stated
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
- Ages
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Started
- 2012-07
- Main results expected
- 2026-10
- Results posted
- Not yet
- Record last updated
- 2026-01-29
What the study is testing
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
Where it runs
United States (1)
- University of California Davis, Sacramento, California